AU734312B2 - Administration of polypeptide growth factors following central nervous system ischemia or trauma - Google Patents

Administration of polypeptide growth factors following central nervous system ischemia or trauma Download PDF

Info

Publication number
AU734312B2
AU734312B2 AU25529/97A AU2552997A AU734312B2 AU 734312 B2 AU734312 B2 AU 734312B2 AU 25529/97 A AU25529/97 A AU 25529/97A AU 2552997 A AU2552997 A AU 2552997A AU 734312 B2 AU734312 B2 AU 734312B2
Authority
AU
Australia
Prior art keywords
administration
growth factor
injury
animals
bfgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU25529/97A
Other languages
English (en)
Other versions
AU2552997A (en
Inventor
Seth P Finklestein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24485972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU734312(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of AU2552997A publication Critical patent/AU2552997A/en
Application granted granted Critical
Publication of AU734312B2 publication Critical patent/AU734312B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of Electric Motors In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Protection Of Generators And Motors (AREA)
AU25529/97A 1996-03-22 1997-03-21 Administration of polypeptide growth factors following central nervous system ischemia or trauma Ceased AU734312B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62044496A 1996-03-22 1996-03-22
US08/620444 1996-03-22
PCT/US1997/005071 WO1997034618A1 (en) 1996-03-22 1997-03-21 Administration of polypeptide growth factors following central nervous system ischemia or trauma

Publications (2)

Publication Number Publication Date
AU2552997A AU2552997A (en) 1997-10-10
AU734312B2 true AU734312B2 (en) 2001-06-07

Family

ID=24485972

Family Applications (2)

Application Number Title Priority Date Filing Date
AU25529/97A Ceased AU734312B2 (en) 1996-03-22 1997-03-21 Administration of polypeptide growth factors following central nervous system ischemia or trauma
AU25823/97A Ceased AU725341B2 (en) 1996-03-22 1997-03-21 Methods for enhancing functional recovery following central nervous system ischemia or trauma

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU25823/97A Ceased AU725341B2 (en) 1996-03-22 1997-03-21 Methods for enhancing functional recovery following central nervous system ischemia or trauma

Country Status (11)

Country Link
US (4) US6407060B1 (enExample)
EP (3) EP1364655B1 (enExample)
JP (2) JP2000507939A (enExample)
KR (1) KR20000064752A (enExample)
CN (1) CN1181885C (enExample)
AT (2) ATE493141T1 (enExample)
AU (2) AU734312B2 (enExample)
CA (2) CA2249368A1 (enExample)
DE (2) DE69740089D1 (enExample)
ES (1) ES2201287T5 (enExample)
WO (2) WO1997034618A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
EP0698094B1 (en) 1993-05-12 2004-02-04 Genetics Institute, LLC Bmp-11 compositions
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
EP0733109B9 (en) 1993-12-07 2006-07-05 Genetics Institute, LLC Bmp-12, bmp-13 and tendon-inducing compositions thereof
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
WO1998020889A1 (en) * 1996-11-15 1998-05-22 Creative Biomolecules Inc Morphogen peptide-induced regeneration of sense perceptory tissues
AU743510B2 (en) 1997-05-05 2002-01-24 Stryker Corporation Therapies for acute renal failure
JP2001526788A (ja) * 1997-05-30 2001-12-18 クリエイティブ バイオモレキュールズ，インコーポレイテッド 組織形態形成および活性を評価するための方法
WO1999028341A2 (en) * 1997-12-04 1999-06-10 Creative Biomolecules, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
DE19837230A1 (de) * 1998-08-17 2000-03-09 Jean Krutmann Neurotrophin-4 zur Behandlung von Tumoren neuroektodermalen Ursprungs
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
CA2380953A1 (en) * 1999-08-18 2001-02-22 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
US6749850B1 (en) 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
EP1223990B1 (en) 1999-10-15 2004-07-28 Genetics Institute, LLC Formulations of hyaluronic acid for delivery of osteogenic proteins
US7060676B2 (en) * 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
WO2001091783A2 (en) 2000-06-01 2001-12-06 Children's Medical Center Corporation Methods and compositions for producing a neurosalutary effect in a subject
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7226587B2 (en) 2001-06-01 2007-06-05 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
US20030022210A1 (en) * 2001-06-01 2003-01-30 Mark Bonyhadi T cell induced tissue repair and regeneration
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US20060259014A1 (en) 2002-05-22 2006-11-16 Surgimark, Inc. Aspirator sleeve and suction handle
SG159387A1 (en) 2002-11-26 2010-03-30 Biocon Ltd In Modified natriuretic compounds, conjugates, and uses thereof
US20040229292A1 (en) * 2002-11-26 2004-11-18 Sebastiano Cavallaro Use of FGF-18 in the diagnosis and treatment of memory disorders
WO2004104185A1 (en) 2003-05-08 2004-12-02 Xcyte Therapies, Inc. Generation and isolation of antigen-specific t cells
EP2789342A1 (en) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
ES2660765T3 (es) 2004-06-21 2018-03-26 The Board Of Trustees Of The Leland Stanford Junior University Genes y rutas expresadas de forma diferencial en trastorno bipolar y/o trastorno depresivo mayor
WO2006012365A2 (en) * 2004-07-20 2006-02-02 University Of Maryland Protease inhibitor
WO2006011600A1 (ja) * 2004-07-29 2006-02-02 Anges Mg, Inc. 脳機能改善のための医薬および方法
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
US8299212B2 (en) 2005-09-20 2012-10-30 Thrasos Therapeutics, Inc. TDF-related compounds and analogs thereof, analogs and bioactive fragments
EP2564864B8 (en) 2005-11-12 2015-05-13 The Board of Trustees of The Leland Stanford Junior University FGF2-related methods for diagnosing and treating depression
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
SI2121142T1 (sl) * 2007-01-25 2012-12-31 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Uporaba GDF-5 za izboljšanje ali vzdrževanje videza kože
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CN101801405A (zh) 2007-08-07 2010-08-11 先进科技及再生医学有限责任公司 包含于酸性水溶液中的gdf-5的蛋白质配方
JP5599778B2 (ja) * 2008-04-14 2014-10-01 デピュイ・シンセス・プロダクツ・エルエルシー 液体緩衝ｇｄｆ−５製剤
US20100204123A1 (en) 2009-02-12 2010-08-12 Mary Elizabeth Pecquet Goad Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease
EP2396026A2 (en) * 2009-02-12 2011-12-21 Stryker Corporation Compositions and methods for minimally-invasive systemic delivery of proteins including tgf- superfamily members
AU2010223268B2 (en) 2009-03-12 2015-04-23 Haase Investments Gmbh Bone morphogenetic protein 2 (BMP2 ) variants with reduced BMP antagonist sensitivity
US20110002897A1 (en) 2009-06-11 2011-01-06 Burnham Institute For Medical Research Directed differentiation of stem cells
EP2352750B1 (en) 2009-09-17 2012-06-13 Stryker Corporation Buffers for controlling the ph of bone morphogenetic proteins
CA2785038A1 (en) 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
CN101822815A (zh) * 2010-04-29 2010-09-08 广东八加一医药有限公司 系列多肽小分子在制备防治缺血性脑血管疾病药物中的应用
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
PH12013500294A1 (en) 2010-08-20 2017-08-23 Wyeth Llc Designer osteogenic proteins
AU2012225784B2 (en) * 2011-03-04 2016-03-17 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
KR101274930B1 (ko) * 2011-06-03 2013-06-17 전남대학교산학협력단 골 형성 또는 혈관신생 촉진용 펩타이드 ｂｆｐ 4 및 이의 용도
WO2013013085A2 (en) * 2011-07-19 2013-01-24 Thrasos Innovation, Inc. Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
EP3881859B1 (en) * 2013-06-11 2024-03-06 President and Fellows of Harvard College Compositions for increasing neurogenesis and angiogenesis
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
IL264439B2 (en) 2016-08-17 2024-08-01 Factor Bioscience Inc non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment
BR112021000018A2 (pt) * 2018-07-03 2021-07-06 Venturis Therapeutics Inc composições e métodos para tratamento de acidente vascular cerebral
CN115190886B (zh) * 2020-02-20 2026-04-28 马斯特里赫特大学 循环bmp10（骨形态发生蛋白10）的检测方法
JP2023526507A (ja) * 2020-05-19 2023-06-21 エレビアン，インコーポレイティド 脳卒中治療のための方法及び組成物
WO2024259004A1 (en) * 2023-06-13 2024-12-19 Bedford Research Foundation Systems and methods of cell transport at ambient temperature

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
EP0501445A1 (en) * 1991-02-27 1992-09-02 Yeda Research And Development Co. Ltd. Pharmaceutical composition comprising interleukin-2
WO1993009802A2 (en) * 1991-11-22 1993-05-27 Genentech, Inc. Tgf-beta to improve neural outcome

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440860A (en) 1980-01-18 1984-04-03 The Children's Medical Center Corporation Stimulating cell growth
US4296100A (en) 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
DE3110560A1 (de) 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
EP0105014B1 (en) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
US4806523A (en) 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4971952A (en) 1986-03-06 1990-11-20 Collagen Corporation Method of treating inflammation with cartilage inducing factor
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
CA1322714C (en) 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
EP0269408A3 (en) 1986-11-26 1989-08-30 Genentech, Inc. Tgf-beta in the treatment of inflammatory disorders
US4797277A (en) 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
US5108753A (en) 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
JPH0262829A (ja) 1988-05-18 1990-03-02 Nippon Kayaku Co Ltd 虚血に基づく傷害の予防及び治療剤
US4983581A (en) 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
HU201095B (en) 1988-06-14 1990-09-28 Richter Gedeon Vegyeszet New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions
EP0423206A1 (en) 1988-07-08 1991-04-24 University College London Analysis of cell modifying substances
WO1990000900A1 (en) 1988-07-20 1990-02-08 Amgen Inc. Method of treating inflammatory disorders by reducing phagocyte activation
US5057494A (en) 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5106626A (en) 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5135915A (en) 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
US5002965A (en) 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
US5118791A (en) 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
US5158934A (en) 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
WO1991005802A1 (en) 1989-10-17 1991-05-02 Creative Biomolecules, Inc. Osteogenic devices
US5108989A (en) 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair
AU666291B2 (en) 1990-06-15 1996-02-08 Carnegie Institution Of Washington Gdf-1
ATE253589T1 (de) 1990-09-26 2003-11-15 Inst Genetics Llc Bmp-5-derivate
DK0643767T3 (da) 1990-10-18 1999-04-26 Stryker Corp Osteogene peptider
JPH06505965A (ja) 1990-11-16 1994-07-07 セルトリックス　ファーマシューティカルズ，インコーポレイテッド β型トランスフォーミング成長因子
EP0564502B1 (en) 1990-11-27 2002-01-30 The American National Red Cross Tissue sealant and growth factor containing compositions that promote accelerated wound healing
WO1992009697A1 (en) 1990-11-30 1992-06-11 Celtrix Laboratories, Inc. USE OF A BONE MORPHOGENETIC PROTEIN IN SYNERGISTIC COMBINATION WITH TGF-β FOR BONE REPAIR
DK0575555T3 (da) 1991-03-11 2001-11-05 Curis Inc Proteininduceret morfogenese
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
WO1992020371A1 (en) 1991-05-10 1992-11-26 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
AU654724B2 (en) 1991-05-10 1994-11-17 Salk Institute For Biological Studies, The Cloning and recombinant production of receptor(s) of the activin/TGF-beta superfamily
DK0591392T3 (da) 1991-06-21 1996-09-30 Genetics Inst Farmaceutiske formuleringer af osteogene proteiner
CA2108770C (en) 1991-06-25 2007-04-03 John M. Wozney Bmp-9 compositions
ATE197611T1 (de) 1991-08-30 2000-12-15 Creative Biomolecules Inc Screeningverfahren von morphogenischen proteinen
EP1637156A1 (en) 1991-08-30 2006-03-22 Curis, Inc. Systemic administration of osteogenic proteins in the treatment of metabolic bone diseases
DE69231062T3 (de) * 1991-08-30 2004-07-29 Creative Biomolecules, Inc., Hopkinton Morphogen-induzierte Modulation von entzündlichen Antworten
KR100259827B1 (ko) 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
AU3129793A (en) * 1991-11-08 1993-06-07 General Hospital Corporation, The Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
DE19525416A1 (de) † 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
AU681594B2 (en) * 1992-07-31 1997-09-04 Stryker Corporation Morphogen-induced nerve regeneration and repair
ES2061380B1 (es) * 1992-11-23 1995-07-01 Boehringer Ingelheim Espana Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
EP0716610B1 (en) 1993-08-26 2006-05-17 Genetics Institute, LLC Human bone morphogenetic proteins for use in neural regeneration
WO1995006656A1 (en) 1993-09-03 1995-03-09 The Regents Of The University Of California Neural tissue affecting factor and compositions
DE69434934D1 (de) 1993-10-14 2007-04-12 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
WO1995024474A1 (en) 1994-03-10 1995-09-14 Human Genome Sciences, Inc. Bone morphogenic protein-10
WO1998020889A1 (en) * 1996-11-15 1998-05-22 Creative Biomolecules Inc Morphogen peptide-induced regeneration of sense perceptory tissues

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
EP0501445A1 (en) * 1991-02-27 1992-09-02 Yeda Research And Development Co. Ltd. Pharmaceutical composition comprising interleukin-2
WO1993009802A2 (en) * 1991-11-22 1993-05-27 Genentech, Inc. Tgf-beta to improve neural outcome

Also Published As

Publication number Publication date
CA2249368A1 (en) 1997-09-25
AU2552997A (en) 1997-10-10
DE69740089D1 (de) 2011-02-10
US6407060B1 (en) 2002-06-18
EP0894004B1 (en) 2003-07-09
JP2000506894A (ja) 2000-06-06
CA2249596C (en) 2011-11-08
CN1181885C (zh) 2004-12-29
ES2201287T5 (es) 2007-10-16
WO1997034618A1 (en) 1997-09-25
KR20000064752A (ko) 2000-11-06
US6214796B1 (en) 2001-04-10
EP0894004B2 (en) 2007-02-21
ATE244574T1 (de) 2003-07-15
ATE493141T1 (de) 2011-01-15
ES2201287T3 (es) 2004-03-16
DE69723429T2 (de) 2004-04-22
CA2249596A1 (en) 1997-09-25
JP2000507939A (ja) 2000-06-27
EP0904093A1 (en) 1999-03-31
JP4847634B2 (ja) 2011-12-28
DE69723429D1 (de) 2003-08-14
EP0904093A4 (en) 2004-11-17
WO1997034626A1 (en) 1997-09-25
EP1364655B1 (en) 2010-12-29
US20030022830A1 (en) 2003-01-30
DE69723429T3 (de) 2007-09-20
EP1364655A1 (en) 2003-11-26
AU2582397A (en) 1997-10-10
CN1219133A (zh) 1999-06-09
EP0894004A1 (en) 1999-02-03
AU725341B2 (en) 2000-10-12
US20010039261A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
US6214796B1 (en) Administration of polypeptide growth factors following central nervous system ischemia or trauma
US5733871A (en) Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
Tuszynski Intraparenchymal NGF infusions rescue degenerating cholinergic neurons
US7304029B1 (en) Neuroprotective effect of growth hormone
CA2234231C (en) Stabilizing formulation for ngf
CA2519803A1 (en) Use of erythropoietin in stroke recovery
Bäckman et al. Effects of transferrin receptor antibody-NGF conjugate on young and aged septal transplants in oculo
US6090781A (en) Stabilizing formulation for NGF
JP2001504123A (ja) Ｃｎｓ障害に対して保護するための成長因子を用いた予備治療
EP1100523A1 (en) Treatment of central nervous system ischemia or trauma with epidermal growth factor-like polypeptides
Gao et al. The therapeutic potentials of neurotrophic factors for diseases of the nervous system
CA2304720A1 (en) Apolipoprotein e/growth factor complexes and methods of use
Zuch et al. Beneficial effects of intraventricularly administered BMP-7 following a striatal 6-hydroxydopamine lesion
EP1832296B1 (en) Compositions based on Midkine for the treatment of chronic stage injury of the heart after ischemia/reperfusion
US6964947B1 (en) Stabilizing formulation for NGF
CA2619721A1 (en) Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease
Klein et al. Neurotrophic factors for experimental treatment of
HK1015261B (en) Stabilizing formulation for ngf
MXPA00001197A (en) Methods for treating neurological deficits

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)